A novel test from Genomic Health Inc. (GHDX) helps predict whether prostate cancer is aggressive or slow-growing, giving patients and doctors more information to shape treatment for the most common tumor found in men, a study found.
Results from the study presented today at the American Urological Association meeting in San Diego may triple the number of men whose cancer can be closely monitored for growth rather than vigorously targeted for destruction, the Redwood City, California-based company said in a statement. The research in 395 men found the Oncotype DX Genomic Prostate Score provided meaningful detail on which tumors were likely to spread.
While only 3 percent of low-risk prostate cancers are life threatening, 90 percent of men choose aggressive care such as surgery and radiation, said Genomic Health Chief Executive Officer Kimberly Popovits. Doctors have few tools to identify those with fast-growing and potentially deadly forms, she said.
“The issue that is so striking in prostate cancer is that treatment comes with significant, life-long and life-changing side effects,” she said. “If you could confidently say to them, you really do have low-risk disease, then you feel very comfortable going into an active surveillance management program,” she said. “This could be practice changing.”
Genomic Health rose 6.4 percent to $36.02 at the 4 p.m. close of New York trading. The shares have gained 24 percent in the past 12 months.
Overtreatment carries high costs for the health-care system and for men who may suffer side effects, including impotence and incontinence. The Oncotype DX test, which evaluates 17 genes in tissue taken during a prostate biopsy to establish the grade and state of the cancer, will be available beginning today. The company will begin talking to insurers about covering the cost immediately, Popovits said.
The test also identified a smaller number of patients who had more aggressive disease, suggesting the men needed immediate treatment. Prostate cancer will be diagnosed in 238,590 men in the U.S. this year, according to the American Cancer Society. It kills almost 30,000 each year, second only to lung cancer.
The test will compete with products such as Myriad Genetics Inc. (MYGN)’s Prolaris. The Oncotype DX is also approved for breast and colon cancer was developed in collaboration with University of California, San Francisco, which conducted the study.
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org